Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non-Current Liabilities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 65.22% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 65.22% year-over-year, with the annual reading at $4.0 million for FY2025, 65.22% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $4.0 million at Phathom Pharmaceuticals, down from $11.5 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $11.5 million in Q4 2024, with the low at $4.0 million in Q4 2025.
  • Average Other Non-Current Liabilities over 4 years is $8.9 million, with a median of $8.6 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities surged 43.33% in 2024, then crashed 65.22% in 2025.
  • Over 4 years, Other Non-Current Liabilities stood at $7.5 million in 2022, then grew by 29.33% to $9.7 million in 2023, then increased by 18.56% to $11.5 million in 2024, then plummeted by 65.22% to $4.0 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $4.0 million, $11.5 million, and $11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.